Given that c‐Myc amplification is associated with poor prognosis in HCC and is a key driver of metabolic reprogramming and cell cycle progression, its inhibition represents a significant therapeutic advantage over conventional kinase inhibitors [47]. This evidence concerns the gene MYC and hepatocellular carcinoma.